1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: Oncologist expectations for immunotherapy in first-line non-small-cell lung cancer

Physician Views: Oncologist expectations for immunotherapy in first-line non-small-cell lung cancer

  • June 2015
  • ID: 3090977
  • Format: PDF
  • By Firstword Pharma

Summary






Much of the debate around cancer immunotherapy at the recent ASCO annual meeting focused on the commercial positioning of a new class of product – the PD-1/PD-L1 inhibitors – in second-line, non-small-cell lung cancer (Physician Views Poll Results – Oncologists give thumbs up for Bristol-Myers Squibb's Opdivo despite biomarker jitters and ViewPoints: Biomarker debate diffused by new US treatment guidelines for Opdivo in non-small-cell lung cancer).

Focus is rapidly switching, however, to the opportunity for these products – either as monotherapies or in combinations – in the much larger first-line NSCLC market. This indication could be as much as twice as large as the second-line market, suggests ISI Evercore analyst Mark Schoenebaum, and represents an intriguing showdown given that different drug manufacturers are implementing markedly different development strategies.

Potentially disruptive Phase I/II data in 30 first-line patients were unveiled by Roche at ASCO, demonstrating that the combination of its PD-L1 inhibitor atezolizumab with chemotherapy produced overall response rates above 60 percent. Not only does this data represent a significant benefit over chemotherapy alone (typical response rates of between 20 percent and 30 percent), but the combination demonstrated a similar side-effect profile to that of chemotherapy and exhibited a strong activity irrespective of PD-L1 status.

These data, while needing to be replicated in larger Phase III studies, are significant given that a prominent narrative related to the emergence of immunotherapy has been an assumption that availability of new treatments could remove chemotherapy from the treatment paradigm. Indeed, Bristol-Myers Squibb – which looks poised to lead the market in second-line NSCLC – currently has no registration-supporting studies under way in first-line NSCLC, which combine its PD-1 inhibitor Opdivo with chemotherapy, while Roche is the only company running large-scale Phase III studies.

While Roche's data has gained recognition from analysts and investors since it was published in abstract form ahead of ASCO, this "ground breaking" approach to first-line treatment remains undervalued, argue analysts at Vontobel. The promising data suggest that Roche could assume leadership in the first-line, add analysts, where use of the combination could erode the second-line opportunity as patients become irresponsive after failure in the first-line setting.

With early-stage data indicating that first-line monotherapy use does not confer significant advantages over chemotherapy, but does provide a benefit in terms of tolerability, there could be an opportunity for monotherapy treatment in PD-L1 positive patients (where efficacy is higher) and those patients (approximately 30 percent) intolerant to chemotherapy.

However, if Roche's atezolizumab plus chemotherapy data can be replicated in Phase III studies, this combination could assume significant usage, particularly given the unprecedented uncoupling from a patient's PD-L1 status at baseline, which could support a very broad label, argue analysts.

With PD-1/PD-L1 monotherapy studies in first-line NSCLC targeting PD-L1-positive patients, checkpoint inhibitor combinations (Bristol-Myers Squibb and AstraZeneca are both extensively studying PD-1/PD-L1 inhibitors with a CTLA-4 inhibitor) are aimed largely at PD-L1-negative patients, but are associated with high toxicity (. In a post-ASCO note to investors, analysts at Credit Suisse were left to question whether Roche's atezolizumab plus chemotherapy data has not only significantly raised the efficacy bar, but will prove less costly than a combination of two immunotherapies.








To better ascertain the potential impact of Roche's data in particular, we are asking US and EU5-based oncologists the following questions…


Based on Phase I/II overall response rate (ORR) data presented at ASCO, how optimistic are you that the combination of atezolizumab plus chemotherapy will improve the survival of first-line NSCLC patients in a meaningful way?
In first-line NSCLC, does the atezolizumab plus chemotherapy data raise the bar for PD-1/PD-L1 monotherapy use in PD-L1-positive patients (demonstrated similar efficacy to chemotherapy, but better tolerability)?
In first-line NSCLC, does the atezolizumab plus chemotherapy data raise the bar for combination PD-1/PD-L1 plus CTLA-4 inhibitor use?
Assuming the Phase I/II data 'translates' in Phase III studies, what level of usage would you expect for the atezolizumab plus chemotherapy combination in first-line NSCLC patients irrespective of PD-L1 status?
Approximately what one-year progression-free survival benefit would a PD-1/PD-L1 inhibitor + CTLA-4 inhibitor combination have to demonstrate in first-line NSCLC to drive moderate-to-significant uptake'hen generic versions of ADF opioids become available do you think they should be required by the FDA to demonstrate…



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Merkel Cell Carcinoma - Pipeline Review, H2 2019

Merkel Cell Carcinoma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Merkel Cell Carcinoma - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Pipeline Review, H2 2019, provides an overview of the Merkel ...

Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2019

Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2019’; Glial ...

Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020

Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020SummaryIndoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is ...


Download Unlimited Documents from Trusted Public Sources

Antimalarials and Antidiabetics Market

  • February 2020
    137 pages
  • Antimalarials  

    Antidiabetics  

    Sodium-Glucose ...  

  • Australia  

    United States  

    North America  

View report >

Pathology Statistics in the US

  • January 2020
    11 pages
  • Therapy  

    Therapy  

  • United States  

    North America  

    World  

View report >

Antimalarials Market in the US - Forecast

  • January 2020
    2 pages
  • Antimalarials  

    Pharmaceutical  

    Dementia  

  • United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on